SEC Form 4 · accession 0001019056-17-000232
Aptevo Therapeutics Inc. · APVO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane A Gross
Officer — See Remarks
Period of report
Feb 24, 2017
Accepted (ET)
Feb 27, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001671584
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.96 | Feb 24, 2017 | A | 33,700 | A | — | Feb 24, 2027 | Common Stock | 33,700 | 156,339 | D |
Explanation of responses
- F1The options vest in three equal annual installments beginning on February 24, 2018.
Remarks
Title - SVP, Research and Non-Clinical Development